CorMedix has successfully completed patient enrolment in a Phase II contrast-induced acute injury study for oral drug candidate CRMD001.

The double blind, placebo-controlled and randomised involves high-risk patients who have chronic kidney disease, and are undergoing a coronary angiography and receiving an iodinated radiocontrast agent.

The study will evaluate the safety and efficacy of CRMD001 on biomarkers of acute kidney injury and kidney function.

The final results of the study are expected to be reported by the end of 2011.